Rafael (NYSE:RFL – Get Free Report) is one of 897 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Rafael to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
Analyst Recommendations
This is a summary of current ratings and target prices for Rafael and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rafael | 1 | 0 | 0 | 0 | 1.00 |
| Rafael Competitors | 7742 | 13824 | 25658 | 1029 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 30.72%. Given Rafael’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Rafael has less favorable growth aspects than its competitors.
Risk and Volatility
Rafael has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, Rafael’s competitors have a beta of 6.23, suggesting that their average share price is 523% more volatile than the S&P 500.
Profitability
This table compares Rafael and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rafael | N/A | N/A | N/A |
| Rafael Competitors | -4,419.36% | -390.22% | -24.21% |
Earnings & Valuation
This table compares Rafael and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Rafael | $980,000.00 | N/A | -1.88 |
| Rafael Competitors | $1.61 billion | $5.20 billion | 550.30 |
Rafael’s competitors have higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
11.3% of Rafael shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 32.9% of Rafael shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Rafael competitors beat Rafael on 8 of the 12 factors compared.
About Rafael
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Receive News & Ratings for Rafael Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rafael and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
